Depo-Provera (medroxyprogesterone acetate) is a long-acting progestin shot used for contraception. It binds progesterone receptors, which are highly expressed in many meningioma brain tumors.
Recent large studies have found that women on Depo-Provera for multiple years have an increased risk of intracranial meningioma (e.g. ~1.5–2.5× risk vs non-users).
This article reviews the pharmacology of Depo-Provera, the biology of meningiomas, and why prolonged progesterone exposure may fuel tumor growth. We include study data on dose and duration risk, clinical signs, and regulatory updates (including the FDA’s 2025 label warning).
If you or a loved one used Depo-Provera and were diagnosed with meningioma brain tumors – or if you have symptoms of meningioma – contact the lawyers at Hissey Mulderig & Friend to find out if you qualify to file a lawsuit by calling 1-866-806-8117 or submitting your information through our free case evaluation form.
➢ What Is Depo-Provera?
Depo-Provera is the brand name for medroxyprogesterone acetate (MPA), a synthetic progestin. It is given as an injection (150 mg IM or subcutaneously) every 3 months to prevent pregnancy.
MPA was FDA-approved for contraception in 1992. It works by binding progesterone receptors in the brain (hypothalamus), suppressing gonadotropin hormones and thus stopping ovulation.
Because it is slowly released from muscle, each shot provides effective contraception for about 3 months. Depo-Provera contains no estrogen, making it suitable for women who cannot take estrogen.
➢ What Is a Meningioma?
A meningioma is a tumor of the brain’s membranes (meninges). These tumors are usually benign (non-cancerous) and slow-growing. Meningiomas account for roughly one-third of all primary brain tumors and are about twice as common in women as in men. They often cause symptoms by pressing on nearby brain tissue.
The most common symptoms include headaches and weakness in an arm or leg; less commonly, seizures, vision changes, or personality changes may occur. Because they grow slowly, meningiomas may become quite large before detection. Many are found incidentally on imaging (MRI/CT).
Treatment is usually surgical removal, with radiation or monitoring for smaller tumors. Despite being benign, meningiomas can seriously affect health through brain compression and, in rare cases, recur as higher-grade tumors.
➢ Progesterone Receptors in Meningiomas
A key reason to worry about Depo-Provera and meningiomas is hormone receptor biology. Both healthy meninges and most meningiomas express progesterone receptors (PR). In fact, studies report that 33–89% of meningiomas contain PR on their cells.
This receptor is functional: meningiomas often grow faster during periods of high progesterone (such as pregnancy or the luteal menstrual phase). Women have a higher incidence (3:1 female:male in childbearing age), suggesting hormones play a role.
Because Depo-Provera is a potent progestin, it can bind these PRs in tumors. Other progestins with high PR affinity (like cyproterone acetate) have been linked to dramatic tumor growth and high risk. Biologically, PR activation promotes cell proliferation in meningiomas, making hormone exposure a plausible tumor driver.
➢ How Medroxyprogesterone Acetate (MPA) Works
MPA (Depo-Provera) is a synthetic progesterone in the progestin family. After injection, it slowly releases into the bloodstream. It exerts its effects primarily by binding progesterone receptors in the hypothalamus to suppress gonadotropin release. The cascade of events prevents ovulation and thickens cervical mucus, achieving contraception.
Importantly, MPA also has high progesterone-receptor affinity – ranked among the strongest progestins – so it can act on any tissue with PR. MPA is concentrated in blood for weeks after injection, meaning prolonged exposure. In short, Depo-Provera provides continuous progesterone-like stimulation to the body’s cells.
➢ Hormonal Influence on Meningioma Tumor Growth
Research shows that sex hormones can influence meningioma behavior. Meningiomas grow noticeably faster during hormonal surges: for example, increases in tumor size have been documented during puberty, the luteal (high-progesterone) phase of the cycle, and pregnancy.
Progesterone and estrogen receptors, when activated, drive tumor cell division. In one series, exposure to progestin drugs (not Depo-Provera specifically) led to high meningioma rates: e.g., women on cyproterone acetate had a seven-fold risk after 6 months and 20-fold after 5 years.
Similarly, other high-dose progestins (nomegestrol, chlormadinone) showed 7–12-times higher risks. These examples reinforce that meningiomas are hormonally sensitive: they often have PR, and progestin exposure can fuel their growth.
By analogy, it is biologically plausible that medroxyprogesterone (the progestin in Depo-Provera) could stimulate meningiomas. MPA is known to cross the blood-brain barrier, and some research has noted that meningiomas formed under progestin therapy show distinct genetic patterns and high PR-positivity.
A laboratory report ranked MPA fourth out of 11 progestins for PR affinity, suggesting it could similarly “feed” PR-positive tumors. In summary, Depo-Provera provides exactly the hormonal signal that meningioma cells can respond to, offering a clear biological mechanism for growth.
➢ Key Studies on Depo-Provera and Meningioma Risk
Several recent studies have examined the potential link between Depo-Provera and meningioma brain tumors in women:
- Large U.S. Insurance Database (2024): Griffin et al. analyzed 117,503 U.S. women with meningioma and over 1 million controls. They found no link with oral MPA, but a 53% higher odds of intracranial meningioma among women who had received injection MPA. The odds ratio (OR) was 1.53 (95% CI 1.40–1.67) for injection users versus non-users. This association was specific to cerebral (not spinal) meningiomas and grew stronger with longer Depo use. In practical terms, prolonged Depo-Provera use was linked to a statistically significant uptick in brain tumors.
- U.S. Cohort Study (2025): Xiao et al. used a national cohort (TriNetX) of ~176,000 matched women. They reported a 2.43-fold relative risk (RR 2.43, 95% CI 1.77–3.33) of a meningioma diagnosis in Depo-Provera users versus non-users. Crucially, this risk emerged only in women who had used Depo for more than 4 years or started it after age 31. No other contraceptive showed such an effect, and oral MPA had only a small effect (RR 1.18). The authors noted a high “number needed to harm” (1152), meaning that although statistically significant, the absolute risk remains low.
- European Case-Control (2022/2023): Roland et al. (France) found a 5.5-fold higher odds of meningioma in women exposed to injectable Depo-Provera. However, very few women in that study used Depo (only ~20 cases), so the estimate is uncertain. Still, it aligns directionally with U.S. data.
In summary, multiple studies now associate long-term Depo-Provera use with higher meningioma risk (especially for intracranial tumors). None prove causality, but combined with the biological mechanism, the evidence is compelling enough that women using Depo-Provera for years should be aware of this risk.
➢ Clinical Implications for Doctors and Patients
For patients and doctors, these findings have practical consequences. A woman who has used Depo-Provera and develops neurological symptoms should be evaluated for a brain tumor. Common meningioma symptoms include:
- Headaches (often worsening)
- Weakness or numbness in an arm or leg
- Vision problems (double vision, loss of vision field)
- Seizures
- Personality or cognitive changes
These depend on the tumor’s location. Meningiomas are typically found by MRI or CT scan. Notably, if a patient on Depo-Provera is diagnosed with a meningioma, current FDA guidance is to stop Depo-Provera immediately. The FDA label now instructs: “Discontinue Depo-Provera CI if meningioma is diagnosed. Monitor patients for signs and symptoms”. This reflects the idea that ongoing progesterone could fuel further tumor growth.
Treatment for meningioma is primarily surgical removal (often curative for benign tumors), sometimes followed by radiation. Drug therapies (like chemotherapies) have limited roles. Even though most meningiomas are benign, they can still significantly impact health and quality of life due to their location.
➢ Regulatory and FDA Label Updates
In late 2025, the FDA formally acknowledged the connection between Depo-Provera and meningioma by updating the drug’s warning label. The new label (approved December 2025) includes a specific “Warnings and Precautions” section on “Meningioma”.
The updated FDA warning label for Depo-Provera states that cases of meningioma have been reported with repeated use of the birth control shot, and notes a “possible increased risk for growth of a meningioma… primarily when the product is used for a long time.”. This is the first time the FDA has mentioned brain tumors in the official Depo-Provera label.
Before this change, U.S. labeling focused on other issues (like bone density loss) and did not warn about brain tumors. The FDA action came after mounting evidence and international precedent.
Notably, health agencies in Europe and Canada have already required similar warnings on their versions of Depo-Provera. The FDA’s new guidance also explicitly advises counseling women with a history of meningioma that continued Depo-Provera use could worsen their condition.
➢ Depo-Provera Users Have Legal Rights
The scientific data has fed a wave of legal claims. As of early 2026, thousands of women have filed lawsuits (now centralized in a Florida MDL) alleging that Pfizer (manufacturer of Depo-Provera) failed to warn about meningioma risk.
Plaintiffs in these lawsuits point to studies and foreign labels to argue that the risk was known and should have been disclosed to U.S. patients. The FDA’s 2025 label revision will likely influence these cases, but litigation is ongoing.
Clinically, the key point is that Depo-Provera now carries an FDA warning about brain tumor risk, reflecting consensus that long-term use raises this hazard.
Any patient with neurological symptoms who has used Depo-Provera should be fully evaluated, and women planning to use Depo-Provera should discuss these risks with their healthcare provider.
For more information about the lawsuits against Depo-Provera or to find out if you qualify to file a claim, contact the law firm of Hissey Mulderig & Friend by calling our office toll-free at 1-866-806-8117, or send us a message using our free Depo-Provera claim submission form at the top of this page.
